Jumanah Qedair  Asmaa A. Youssif , Reham Shehada, and Hashem Abu Serhan

Introduction: 

• Neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME) are leading causes of visual impairment worldwide
• Faricimab is a novel dual-pathway agent targeting VEGF-A and angiopoietin-, demonstrates proven efficacy in improving anatomical and visual outcomes
• Intraocular inflammation (IOI), although rare, is a recognised complication of intravitreal therapy                                                                                                                                                                                                                        For Methods & Results all Visual 

• Conclusion

  • Faricimab is an effective anti-VEGF therapy for nAMD and DME
  • Intraocular inflammation (IOI), although uncommon, represents a clinically significant risk
  • Vigilant post-injection monitoring is essential to reduce sight-threatening complications
  • Further long-term real-world studies are needed to:
    • Better define IOI risk
    • Standardise definitions
    • Optimise monitoring strategies